Accéder au contenu
Merck

Nanoparticle composite TPNT1 is effective against SARS-CoV-2 and influenza viruses.

Scientific reports (2021-04-24)
Sui-Yuan Chang, Kuo-Yen Huang, Tai-Ling Chao, Han-Chieh Kao, Yu-Hao Pang, Lin Lu, Chun-Lun Chiu, Hsin-Chang Huang, Ting-Jen Rachel Cheng, Jim-Min Fang, Pan-Chyr Yang
RÉSUMÉ

A metal nanoparticle composite, namely TPNT1, which contains Au-NP (1 ppm), Ag-NP (5 ppm), ZnO-NP (60 ppm) and ClO2 (42.5 ppm) in aqueous solution was prepared and characterized by spectroscopy, transmission electron microscopy, dynamic light scattering analysis and potentiometric titration. Based on the in vitro cell-based assay, TPNT1 inhibited six major clades of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with effective concentration within the range to be used as food additives. TPNT1 was shown to block viral entry by inhibiting the binding of SARS-CoV-2 spike proteins to the angiotensin-converting enzyme 2 (ACE2) receptor and to interfere with the syncytium formation. In addition, TPNT1 also effectively reduced the cytopathic effects induced by human (H1N1) and avian (H5N1) influenza viruses, including the wild-type and oseltamivir-resistant virus isolates. Together with previously demonstrated efficacy as antimicrobials, TPNT1 can block viral entry and inhibit or prevent viral infection to provide prophylactic effects against both SARS-CoV-2 and opportunistic infections.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Solution de substrat 3,3′,5,5′-tétraméthylbenzidine (TMB), peroxidase substrate